Savara Inc.'s (NASDAQ:SVRA) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 14% Over Last Week
Did Savara Inc. (SVRA) Receive a Good Rating From Wall Street Analysts in Q1?
Savara Shares Climb on $100 Million Share Offering
By Don Nico Forbes Shares in Savara rose 8% after the company said it plans to raise roughly $100 million in an underwritten share placing. The biopharmaceutical company said it will offer 26.2 mill
Express News | Savara Inc: Prices Offering of 26.2 Mln Shares at $3.81/Share
Express News | Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
Savara Is Maintained at Buy by Guggenheim
Savara Is Maintained at Buy by Guggenheim
Oppenheimer Adjusts Price Target on Savara to $15 From $11, Maintains Outperform Rating
Savara (SVRA) has an average buy rating and price target range of $7 to $16, according to analysts polled by Capital IQ. Price: 3.94, Change: +0.10, Percent Change: +2.47
Evercore Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $7
Evercore analyst Liisa Bayko maintains $Savara(SVRA.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 44.5% and a total average
Guggenheim Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $10
Guggenheim analyst Vamil Divan maintains $Savara(SVRA.US)$ with a buy rating, and adjusts the target price from $7 to $10.According to TipRanks data, the analyst has a success rate of 54.0% and a tota
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $7 to $15
On Jun 27, major Wall Street analysts update their ratings for $Savara(SVRA.US)$, with price targets ranging from $7 to $15.Jefferies analyst Andrew Tsai maintains with a buy rating, and maintains the
Express News | Savara Inc : Guggenheim Raises Target Price to $10 From $8
Savara Is Maintained at Buy by HC Wainwright & Co.
Savara Is Maintained at Buy by HC Wainwright & Co.
Express News | Savara, Inc. : H.c. Wainwright Raises Target Price to $10 From $6
Savara Down Nearly 11%, on Pace for Largest Percent Decrease Since March 2023 -- Data Talk
Savara, Inc. ( SVRA ) is currently at $3.39, down $0.41 or 10.76% --Would be lowest close since Oct. 25, 2023, when it closed at $3.27 --On pace for largest percent decrease since March 10, 2023, wh
Savara Price Target Raised to $15.00/Share From $11.00 by Oppenheimer
Savara Price Target Raised to $15.00/Share From $11.00 by Oppenheimer
Savara Is Maintained at Outperform by Oppenheimer
Savara Is Maintained at Outperform by Oppenheimer
Savara Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/26/2024 341.83% Oppenheimer $11 → $15 Maintains Outperform 05/21/2024 224.01% Oppenheimer $9.5 → $11 Ma
Express News | Savara Shares Are Trading Lower, Pulling Back After Initially Rising on Phase 3 IMPALA-2 Clinical Trial Results
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
The latest trial study from Savara Inc (NASDAQ:SVRA) met its primary endpoint.The company released results from Phase 3 IMPALA-2 trial of molgramostim 300 mcg administered once daily by inhalation wit
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
Health care stocks were mixed pre-bell Wednesday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.5% recently. Savara (SVRA) rose past 17% aft